Skip to main content

Table 1 Summary of baseline clinical characteristics

From: A 14-week randomized, placebo-controlled, double-blind clinical trial to evaluate the efficacy and safety of ginseng polysaccharide (Y-75)

Characteristics Y-75 (n= 36) Placebo (n= 36)
Age, years 57.42 ± 4.09 58.69 ± 4.34
Female sex, n (%) 34 (94.44) 36 (100)
Weight, kg 58.39 ± 5.42 58.83 ± 7.18
Height, cm 157.56 ± 4.69 158.28 ± 4.99
Menopause, n (%) 27 (87.10) 32 (94.12)
Medical history, n (%)   
Musculoskeletal and connective disease 12 33.33) 15 (41.67)
Cardiovascular disease 7 (19.44) 8 (22.22)
Metabolism and nutritional disease 5 (13.89) 6 (16.67)
Gastrointestinal disease 4 (11.11) 2 (5.56)
Vital sign   
Systolic BP, mmHg 109.86 ± 10.72 108.89 ± 12.25
Diastolic BP, mmHg 75.69 ± 8.12 74.31 ± 9.79
Heart rate 69.78 ± 4.85 69.56 ± 6.22
WBC (10 9 /L) 5.68 ± 1.47 5.25 ± 1.36
Neutrophils (%) 49.59 ± 11.17 49.48 ± 9.29
Lymphocytes (%) 39.63 ± 8.04 40.98 ± 8.69
Monocytes (%) 6.86 ± 1.56 6.58 ± 1.41
Eosinophils (%) 2.15 ± .55 2.46 ± 1.90
Basophils (%) 0.53 ± 0.38 0.50 ± 0.28
  1. Data presented as mean ± SD of number (%). All differences were non-significant.